Crizotinib Clinical Trials

11 actively recruiting trials across 2 locations

Also known as: Alectinib, Brigatinib, Carboplatin, Lorlatinib, MET Tyrosine Kinase Inhibitor PF-02341066, PF-02341066, PF-2341066, Paclitaxel, Pemetrexed, Savolitinib, XALKORI, XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg, Xalkori, immune checkpoint inhibitors

Filter by location:

Other9 trials

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

Phase 3

ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma

Phase 2

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Phase 2

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC

Phase 2

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Phase 2

Safety and Efficacy of Xalkori ROS1

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

Phase 2

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Phase 2

The Drug Rediscovery Protocol (DRUP Trial)

Phase 2

Los Angeles, California1 trial

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

UCLA Medical Center

Phase 1/2

Houston, Texas1 trial

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

M D Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.